Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) initiated the shares trading at $4.42 and showed negative change of -3.85% while the stock’s final trade was registered at $ 4.25. However, its previous closing price was seen at $4.42. The stock negotiated total number of 1.14 million shares as compared to 3 months average volume of 843.99 thousand shares.
The stock price demonstrated downbeat change from its 50 day moving average of 2.78 and had been up from its 200 Day Moving Average of 2.34.
The average true range of Biostar Pharmaceuticals, Inc.’s (BSPM) is recorded at 0.95 and the relative strength index of the stock stands 57.10. The stock price is going above to its 52 week low with 293.52% and lagging behind from its 52 week high with -45.30%. Analyst recommendation for this stock stands at 1.00. A look on the firm performance, its monthly performance is 240.00% and a quarterly performance of 115.74%. The stock price is trading upbeat from its 200 days moving average with 39.23% and up from 50 days moving average with 80.88%.
Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) climbed +5.83% and ended at $2.18 greater than previous closing price of $2.06. The total 892.37 thousand shares were bought and sold throughout the most recent trading session more than average volume of 196.28 thousand shares.
Conatus Pharmaceuticals Inc.’s (CNAT) has price-to-cash ratio of 1.42 . A look on the firm performance, its monthly performance is -5.63% and a quarterly performance of -21.01%. The stock price is moving up from its 20 days moving average with 5.01% and isolated negatively from 50 days moving average with -5.58%.
The stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as “Buy” from “0” brokerage firms and “0” brokerage firms say as “Strong Buy”. “0” brokerage firms have suggested “Sell” for the company. “0” brokerage firms have recommended as a “Hold”. Strong Sell rating was given by “1” brokerage firms. The Company has average brokerage recommendation (ABR) of “0” based on consensus of the ZACKS brokerage firms.